Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens

OBJECTIVE: CYP2C19 metabolic activity influences the efficacy of Helicobacter pylori eradication therapies comprising PPIs. Rabeprazole (RPZ) and esomeprazole (EPZ) are PPIs not extensively metabolized by CYP2C19. The aim of this study was to elucidate whether or not first-line triple therapies usin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Intern Med
Autors principals: Shimoyama, Tadashi, Chinda, Daisuke, Sawada, Yoshihiko, Komai, Kazuo, Chiba, Hironobu, Saito, Yoshiharu, Sasaki, Yoshio, Matsuzaka, Masashi, Fukuda, Shinsaku
Format: Artigo
Idioma:Inglês
Publicat: The Japanese Society of Internal Medicine 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519461/
https://ncbi.nlm.nih.gov/pubmed/28674348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.56.7823
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars